|
|
Day 1
9 June 2010 8am - 5:30pm
Day 2
10 June 2010 8am - 5:30pm
|
|
|
Friday, 11 June 2010Friday, 11 June 2010
8am Registration and refreshments9am Chairman opening remarks
Vice President and Global Head of the Influenza Strategy Liaison , Novartis Vaccines and Diagnostics
KEY DRIVERS FOR ASIA’S INFLUENZA VACCINE BUSINESS9.05am The need for improved influenza prevention: A public health and industrial perspective
- Developing better influenza vaccines for improved influenza prevention
- Defining the role of the public health community to improve influenza control and prevention
- Emphasizing the role the industry can play in supporting and strengthening influenza pandemic preparedness
Global Scientific Communication and Public Affairs Director for Influenza Vaccines, Solvay Biologicals BV
9.35am Discussing the current and future challenges for influenza
- Defining the burden of disease
- Assessing future pandemic threats in the region
- Pathogenesis: the virus-host interaction
Chair Professor of Microbiology at The University of Hong Kong, Virologist at the Queen Mary Hospital and the Scientific Director, HKU-Pasteur Research Centre at Hong Kong
10.05am Analyzing and forecasting Asia’s influenza vaccine market to effectively address the region’s evolving needs
- Determining the right strategies in predicting the regions demand and supply requirement for pandemic and seasonal flu vaccine
- Identifying the main drivers and resistors in effectively addressing Asia’s influenza market
- Developing a strategy for the control and pandemic preparedness
Director, Medical Affairs and Public Policy, Asia Pacific, Sanofi Pasteur
10.35am Morning refreshment NEWLY IMPROVED INFLUENZA VACCINES11.15am Keynote: Influenza pandemic 2009 – learnings for public health and the vaccine industry
- Discussing uncertainties the industry and goverments faced during the initial phase of the pandemic
- How did the industry and governments respond to such situation?
- What are the learnings from the swH1 pandemic on future strategies for vaccine supply?
Vice President and Global Head of the Influenza Strategy Liaison , Novartis Vaccines and Diagnostics
11.45am Developing universal cross-protective influenza virus vaccines
- Impact of different methods of whole virus inactivation on vaccine efficacy
- Demonstration of complete heterotypic protection in animal models
- Possibilities for novel avian and human influenza vaccine development in Asia
Executive Chairman, Gamma Vaccines
12.15pm Human Viral Challenge Studies - Accelerating proof of concept for vaccines against respiratory viruses
- Human Viral Challenge Studies to demonstrate proof of concept for new drugs and vaccines against influenza, RSV and HRV
- Advantage of Human Viral Challenge Studies which can be set up, recruited into and completed quickly with proof of concept achieved within months rather than years
- Reviewing the history of such studies, the viruses used and in particular the clinical and virological endpoints that can be measured
Chief Executive Officer, Retroscreen Virology
12.45pm Development challenges for a synthetic universal influenza vaccine entering the clinical phase
- Depo vaccine and high density antigen technology platforms underpinning the synthetic universal vaccine
- Assessing various development pathway for a synthetic universal influenza vaccine
- Targeting market needs for both seasonal and pandemic flu market segments
Chief Executive Officer, Immune Targeting Systems (ITS) Ltd
2.30pm Use of live attenuated influenza vaccine for pandemic influenza
- The benefits of live attenuated influenza vaccine for emerging pandemic strains
- Case study of LAIV development for the 2009 H1N1 pandemic
- Future development of LAIV in support of pandemic preparedness
3pm Discussing the latest developments of the H1N1 vaccine
- Presentation of the clinical trials results of H1N1 vaccine
- Accelerating the development of H1N1 vaccine to address the growing demand
- Addressing the safety concerns of the vaccine through stringent testing and evaluation
3.30pm Strategies to face the challenges of delivering broadly effective pandemic vaccines at the right place and at the right moment
- Lessons learned from the 2009 pandemic
- Cost-effective strategies for global vaccine delivery
- Plant-based vaccines as first responder solution
- Clinical data from plant-derived VLP-based H5N1 vaccine
4pm Successful case study of H1N1 vaccine development and preparedness in Korea
- Presenting H1N1 vaccine production
- Discussing the clinical trials approvals process
- Establishing vaccination program in Korea
4.30pm Afternoon refreshment5pm Roundtable discussionThis round table discussion session is an open moderated session where delegates are divided into groups to discuss a set or topics. This session aims to address the issues, problems and ideas of each delegate. Moderated by key industry experts, the round table discussion will ensure debate and discussion on thought-provoking and controversial issues with industry peers. 5pm Roundtable 1: Investigation various options to control influenzaDeveloping an influenza pandemic preparedness plan is a must. Planning for a pandemic response program requires a global perspective and concerted effort. Various stakeholders have to work together to devise a strategy in order to make Asia pandemic ready. What are the necessary joint efforts to make prevention of new influenza pandemic possible? What are the different approaches in preventing a pandemic? How Asia pro-actively respond to an eventual pandemic? 5pm Roundtable 2: Meeting demand with sufficient influenza vaccine supply in Asia
Balancing the demand and supply of influenza vaccine is tough especially when a pandemic strikes. Careful planning is necessary in order to predict the possible market demand in each region. Timely production of the vaccine is one concern but then next challenge is how fast can you bring it to market. What are the various ways to reduce production time and at the same time increase speed to market? Are there new manufacturing innovations that have made a big difference in the influenza vaccine industry? 5.30pm Chairman’s closing remarks |
|
|
|
|
|
|
|
|
|
|
